

ClarityDX Prostate is a test that combines lab results for;

# What is ClarityDX Prostate?

	✓ Total PSA ✓ Percent free PSA							
state?	and three to five clinical features;							
	✓ Age	<ul> <li>✓ Previous negative biopsies</li> </ul>	✓ DRE	<ul> <li>✓ Prostate</li> <li>volume</li> <li>(MRI)</li> </ul>	✓ PI-RADS (MRI)			

These lab results and clinical features are used to calculate the risk of having clinically significant prostate cancer, defined as Gleason Grade Group 2 or higher, (GG  $\ge$  2) on prostate biopsy.

The ClarityDX Prostate test is indicated for use at the primary care level to aid in the decision for prostate biopsy in men who have an elevated total PSA and/or an abnormal DRE and without a previous history of prostate cancer(3-8).



Why use

The ClarityDX Prostate test was developed using data from five independent cohorts totaling 3,448 men.

## ClarityDX Prostate?

### The study demonstrates

that ClarityDX Prostate\* is up to 4X more specific than PSA at detecting clinically significant prostate cancer. \* ClarityDX Prostate +MRI+DRE

## This improved specificity

can be used to better inform clinical decisionmaking regarding the need for further screening.





Test performed by Nanostics Clinical Lab CPSA Accreditation Facility No. L0526000

#### The ClarityDX Prostate

test is flexible to the availability of MRI and DRE data due to four optimized risk models that provide high accuracy for predicting clinically significant prostate cancer in a variety of clinical settings.

	Validation				
	AUC	Sensitivity	Specificity	PPV	NPV
PSA	0.72	95%	12%	46%	78%
% Free PSA	0.72	95%	11%	46%	72%
1 ClarityDX Prostate	0.82	95%	32%	52%	89%
2 ClarityDX Prostate DRE	0.82	95%	35%	54%	91%
3 ClarityDX Prostate MRI	0.87	95%	45%	50%	94%
4 ClarityDX Prostate + MRI + DRE	0.87	95%	47%	51%	94%
AUC: Receiver Operating Characteristic Area Under th	NPV: Negative Predictive Value		<b>PPV:</b> Positive Predictive Value		

ClarityDX Prostate is intended to be done as a reflex test after elevated PSA levels are detected and before a prostate biopsy. This fits perfectly within the Canadian Urology Association (CUA) guidelines as an adjunctive strategy to be performed after a high PSA level is detected and before a biopsy and or MRI is performed (3).




Care Path with

**ClarityDX** Prostate

### Interpreting ClarityDX **Prostate Results**

The ClarityDX Prostate Test Report provides the patient's total PSA, % free PSA, and the ClarityDX Prostate Risk Score. The risk score is provided as a percent probability of  $GG \ge 2$  prostate cancer and is reported with the patient's risk associated with their age group. A risk score above the threshold indicates a high risk for clinically significant prostate cancer.



Wallis et al. (2024) JCO 42, e17105-e17105.

